MOEBIUS HANS 4
4 · Athira Pharma, Inc. · Filed Jun 6, 2023
Insider Transaction Report
Form 4
MOEBIUS HANS
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-02−7,882→ 0 totalExercise: $1.35Exp: 2029-08-14→ Common Stock (7,882 underlying) - Award
Common Stock
2023-05-18$2.41/sh+7,764$18,711→ 73,600 total - Exercise/Conversion
Common Stock
2023-06-02$1.35/sh+7,882$10,641→ 81,482 total
Footnotes (4)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c).
- [F2]The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022.
- [F3]In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023.
- [F4]One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.